|
|
|
|
Further treatments: A small cross-over trial with aspirin 2 x 650 mg has recently shown some benefit on fatigue in MS [Wingerchuk 2005]. Interestingly some of the large earlier trials using immunomodulating agents suggest that they may also reduce fatigue, but few of these trials formally included measurements of fatigue within the list of their secondary endpoints [IFNB study group 1993; PRISMS 1998; Jacobs 1996]. Although in one other study the effect of interferons and glatirameracetate GLAT ; on fatigue was measured using the Fatigue Impact Scale. 24, 8% of patients receiving GLAT reported a reduced degree of fatigue [Metz 2004]. Recommendations Exclusion of other treatable causes of fatigue like depression, infections, hypothyroidism, and sedatives Aerobic training, energy conservation training, multimodal rehabilitation Cooling of the body or of extremities. Drug treatment with amantadine few adverse effects ; . If insufficient effect: Modafinil, 4aminopyridine, L-acetyl-carnitine. Information based on data published by the U.S. Food and Drug Administration at fda.gov, accessed 3 30 2005, with modifications in March 2006 based upon new prescribing information for oseltamivir for pediatric prophylaxis. Please note that the role of amantadine and rimantadine in prophylaxis or treatment of pandemic influenza is uncertain; these drugs are not currently recommended by CDC for prophylaxis or treatment of circulating strains of influenza A in the 2005-2006 influenza season.
The emergency room after attempting suicide by slashing both of his wrists with a razor blade. On admission, his history and the results of a mental status examination were consistent with an initial episode of severe major depression. There was no evidence of delusions, hallucinations, or a thought, perceptual, or cognitive disturbance. Results of a physical examination, including an extensive hematological and metabolic screening, as well as an ECG and chest X-ray, revealed no significant abnormalities. His medical history was significant for the presence of osteoarthritis, gout, gastritis, and glaucoma, for which he took ibuprofen, sucralfate, and colchicine and used a betaxolol hydrochloride opthalmic solution. Bupropion treatment was started at a dose of 75 mg day and titrated to a dose of 100 mg t.i.d. over the next 7 days. Despite a gradual improvement in mood, Mr. A began to exhibit some paranoid ideation on the fourth day of bupropion treatment. Mr. A's paranoia increased over the next 3 days, and he began experiencing auditory hallucinations. His dose of bupropion was decreased to 25 mg day. Haloperidol treatment was initiated at a dose of 2 mg day and subsequently titrated to 5 mg day over the next 5 days. During the following week, Mr. A's psychotic symptoms decreased until they were entirely absent. Haloperidol treatment was discontinued, and his dose of bupropion was again titrated upward, this time to a final dose of 25 mg t.i.d. He did not experience a recurrence of either depressive or psychotic symptoms during the next 3 months of follow-up care. Seven reports of emergent psychosis or delirium with psychotic features from bupropion treatment exist in the literature 28 ; . After reviewing these case reports and a case series, one can conclude that bupropion-induced psychosis occurs primarily in patients with certain risk factors. Vulnerable patients include those with a history of psychosis or those who are taking other dopaminergic medications such as amantadine or levodopa. By blocking dopamine uptake, bupropion may cause dopaminergic overdrive 2 ; and thereby precipitate psychosis. This case, coupled with the relative absence of reports of bupropion-induced psychosis in non-predisposed individuals, suggests that the elderly may be more vulnerable to bupropion-induced psychosis and other toxic effects than younger adults with depression. A report demonstrated that the half-life of bupropion is prolonged in the elderly and that the elderly accumulate bupropion metabolites 9 ; . Potential toxic effects, including seizures and psychosis, may result from high bupropion plasma levels and the accumulation of bupropion metabolites in the elderly or in those with impaired liver function 10 ; . Clinical reports in the elderly demonstrate that lower 75 to 225 mg day ; doses of bupropion are associated with fewer side effects and equal efficacy to those found with higher doses 11, 12.
Acknowledgements . 145 References . 147 Appendix 1 All studies identified by the NI treatment systematic review . 171 Appendix 2 Jadad instrument used for rating reported methodological quality . 175 Appendix 3 Methodology for meta-analysis of mean time to recovery type outcomes for economic model . 177 Appendix 4 All studies identified by the NI prophylaxis systematic review . 199 Appendix 5 All studies identified by the amantadine systematic review of use in children and the elderly . 201. Well tolerated. Such a need may exist in the following situations: i ; An outbreak is diagnosed in a closed institutional setting; or ii ; In the family setting; or iii ; When influenza is causing illness in the community even as vaccine is being administered. An outbreak is diagnosed in a closed institutional setting: Prophylaxis in a closed institutional setting may be initiated when an outbreak is diagnosed evidence grade IIB ; . An outbreak may be diagnosed if at least two residents develop acute influenza-like illness within 72 h of each other and have laboratory-proven influenza illness confirming the transmision of influenza. Amantadine, zanamivir and oseltamivir have all been used for outbreak control in nursing homes. Zanamivir and oseltamivir may be preferable to amantadine evidence grade IB ; . Usually, chemoprophylaxis for outbreak control in an institution is administered for at least 10 days. Prophylaxis may be discontinued if eight or more days have elapsed since the onset of the last case of influenza in the unit. If new cases continue to appear, then prophylaxis will, by corollary, need to be continued so that this strategy could become, in effect, seasonal prophylaxis. In the family setting: When influenza occurs in the family setting, postexposure chemoprophylaxis in unaffected members should be considered to reduce illness in the family evidence grade IA ; . Unaffected family members should be started on chemoprophylaxis as soon as possible after recognition of influenza-like illness in the index case. Amantadine, zanamivir and oseltamivir are all recommended for postexposure prophylaxis when the virus is susceptible. The duration of prophylaxis is usually seven to 10 days. The index case may be treated with the recommended five-day course of zanamivir or oseltamivir, but not amantadine. Treatment of the index case with amantadine has resulted in failure of amantadine prophylaxis in other family members due to the rapid development of amantadine-resistant mutants in the treated index case. If amantadine is the only option available for the index case in a household, do not use it for prophylaxis for other family members. When influenza is causing illness in the community even as vaccine is being administered: Chemoprophylaxis may be used to protect individuals until vaccine-induced immunity develops evidence grade IIIB ; . Chemoprophylaxis should be continued for two weeks after appropriate vaccination one or two doses ; . When vaccine is coadministered, which is expected to protect against a circulating strain causing illness in the community, chemoprophylaxis should be continued until vaccine-induced immunity is likely to have developed. The time for vaccine-induced immunity to develop may be seven to 10 days if the virus strains in the vaccine are drift variants of strains that have been causing the illness in one or more previous years, such that some heterologous immunity is likely to exist that can be boosted by the current vaccine. Where the vaccine contains a virus arising as a result of antigenic shift ie, a pandemic strain ; , vaccine-induced immunity may require two or more doses of the vaccine. Chemoprophylaxis will need to be continued until it is probable that immunity has! As functional capacity worsens, chorea lessens and dystonia intensifies Feigin et al., 1995; Louis et al., 1999 ; . Approximately 12% of the patients suffer from adult-onset dystonia-predominant HD cohort of 127 patients ; Louis et al., 2000 ; . Subjects with a younger age of onset had more severe dystonia, bradykinesia and eye movement abnormalities relative to chorea in this study. However, the majority of HD patients exhibit some dystonia. The prevalence of dystonia in HD of any severity was 95% in a cohort of 42 HD patients Louis et al., 1999 ; . The dystonia is usually present in several body regions and is manifested by a variety of movements and postures not typical of idiopathic torsion dystonia. The most prevalent types of dystonia are internal shoulder rotation 64% ; , sustained fist clenching 47% ; , excessive knee flexion 43% ; and foot inversion 43% ; . Classical forms of adult-onset focal dystonia such as torticollis 14% ; or blepharospasm 10% ; occurred with a lower frequency. In 88% of patients, there were more than two types of dystonia and, in the average patient, three to four types of dystonia. Although the dystonia is not troublesome to most HD patients Louis et al., 1999 ; , it may cause functional impairment in others, and subsequently require therapeutic intervention. Generally, treatment of dystonia is exclusively difficult and largely ignored in HD research. Quinn and Marsden 1984 ; undertook a randomized, placebo-controlled, double-blind crossover trial of sulpiride and found a reduction in total dyskinesia score in 11 HD patients, although functional improvement was not seen. Other newer agents such as riluzole Rosas et al., 1999; Seppi et al., 2001 ; , amantadine Verhagen Metman et al., 2002 ; or olanzapine Bonelli et al., 2002a ; , could not significantly improve dystonia scores, although they were successful in reducing chorea. Astonishingly, no single case report on botulinum toxin in focal HD dystonia is available, even though this is the treatment of choice in these forms of dystonia today. Oral administration of a high dosage of anticholinergic drugs is recommended for the treatment of dystonia. Diazepam is another choice, and the drug usually does not cause any adverse effects in cases, with good results being achieved. Selective peripheral denervation remains an effective form of treatment for patients with secondary botulinum toxin treatment failure, but is not indicated in HD probably due to the progressive course of the disease. Finally, a renaissance of functional surgical ablative procedures has taken place, with high frequency deep brain stimulation and reminyl. Cerebrospinal fluid CSF ; pressure in excess of 250 mm CSF is usually a manifestation of serious neurologic disease. Intracranial hypertension is most often associated with rapidly expanding mass lesions, CSF outflow obstruction, or cerebral venous congestion. I. Clinical evaluation A. Increased intracranial pressure may manifest as headache caused by traction on pain-sensitive cerebral blood vessels or dura mater. B. Papilledema is the most reliable sign of ICP, although it fails to develop in many patients with increased ICP. Retinal venous pulsations, when present, imply that CSF pressure is normal or not significantly elevated. Patients with increased ICP often complain of worsening headache, in the morning. Causes of Increased Intracranial Pressure Diffuse cerebral edema Meningitis Encephalitis Hepatic encephalopathy Reye's syndrome Acute liver failure Electrolyte shifts Dialysis Hypertensive encephalopathy Posthypoxic brain injury Lead encephalopathy Uncompensated hypercarbia Head trauma Diffuse axonal injury Space-occupying lesions Intracerebral hemorrhage Epidural hemorrhage Subdural hemorrhage Tumor Abscess Hydrocephalus Subarachnoid hemorrhage Meningitis Aqueductal stenosis Idiopathic Miscellaneous Pseudotumor cerebri Craniosynostosis Venous sinus thrombosis. Drugs Antimicrobics Dirithromycin Erythromycin Mupirocin Roxithromycin Piperacillin-tazobactam Nitrofurantoin Clinafloxacin Fleroxacin Levofloxacin Lomefloxacin Ofloxacin Antifungals Fluconazole Terconazole Antivirals Amantdaine Acyclovir Famciclovir Valacyclovir Ganciclovir Foscarnet Abacavir Amprenavir Didanosine Lamivudine Nevirapine Stavudine Zidovudine 1-5 0.6-5.9 5 * , + * * * , # + [120] [110] [111] [112] [118] [117] [290] [291] [108] [106] [292] [107] [293] 7-13 9 * , $ [103] [104] 2-9 8.2 9 [285] [97] [102] [96] [100] [286] [92] [93] [287] [288] [289] % of Headache Notes Ref and revia. If patients have mild symptoms, but feel they are in need of therapy, then amantadine or a dopamine agonist would be reasonable. Rigorous study as being the most effective agent. Most articles are either case reports or reports of open-label studies. Few placebo-controlled studies have been completed. Most literature on this issue centers around the use of badrenergic blocking agents, anticholinergic agents, the atypical antipsychotic agent clozapine, and the benzodiazepines. There have also been a few other reports of less commonly used regimens as well. Currently, the b-adrenergic blocking agents, such as propranolol, have emerged as a top choice to treat akathisia. They have been studied extensively, and the "weight of evidence" points toward propranolol as being useful in treatment of akathisia.66 In a series of cases of antidepressant-related akathisia, Zubenko et al.54 noted that propranolol "appeared to be superior to either the anticholinergic agent or the benzodiazepine" to treat the akathisia. Case reports have described the effective use of propranolol to treat akathisia induced by conventional antipsychotics, atypical antipsychotics, 67 tricyclic antidepressants, 53 and SSRIs.68 Sachdev69 suggested that doses of propranolol as low as 60 mg day are sufficient to reduce the restlessness associated with akathisia. Still, care must be exercised when using propranolol in elderly patients. If the patient is taking an antipsychotic medication with 1 blockade such as all of the currently available atypical antipsychotic agents ; , the addition of b blockade could result in a decrease in peripheral vascular resistance and cardiac decompensation.8 The anticholinergic agents and antihistamines such as diphenhydramine and cyproheptadine ; have long been used to treat akathisia.2 Case reports have identified benztropine and trihexiphenidyl as being very effective for the treatment of this side effect.45 Procyclidine and biperiden have been reported to be useful in the treatment of akathisia.5, 70 One study found that a 5-mg dose of biperiden delivered intravenously relieved akathisia significantly faster than when it was administered intramuscularly.70 The mean onset of action was 1.6 minutes for intravenous biperiden and 30.5 minutes for intramuscular biperiden. Akathisia was completely ameliorated by biperiden in all of the study patients. It has been suggested that anticholinergic agents for treatment of akathisia may have their most robust effects in younger patients.66 Diphenhydramine 25 mg t.i.d. ; is often effective in the treatment of akathisia.2, 5 A doubleblind study comparing cyproheptadine and propranolol found that cyproheptadine was as effective as propranolol for the treatment of neuroleptic-induced akathisia.71 The doses were 16 mg day for cyproheptadine and 80 mg day for propranolol. Amantadihe is another agent that has been and dramamine. What then determines where the burden of proof lies? Often the question will turn on the form in which a legal rule is traditionally stated.33 If an issue is commonly listed among the constituent elements of a cause of action, the burden of proof will be said to be on the plaintiff. If the issue is commonly referred to as a factor leading to the avoidance of liability, the burden of proof will be on the defendant. Thus, in torts law the burden of proving negligence rests on the plaintiff, 34 while the burden of proving contributory negligence is on the defendant.35 In marine insurance, the burden of proving that the ship was lost by perils of the sea rests on the shipowners.36 However, legal rules usually assume particular forms for reasons of clarity of exposition quite unrelated to questions of burden of proof. In one case, Sir Wilfred Greene MR remarked. Tivity which, after 1 hour not shown ; became focalized and conditions returned to the original control panel A ; . These experiments show that TTX is capable of diminishing or abolishing amantadine-induced pacemaker-activity indirectly by decreasing the availability of the sodium-carrying system responsible for the upstroke of the action potential, thereby diminishing the likelihood of propagation from the amantadineinduced dominant pacemaker. Some Properties of Amantadine-induced SDD's In preparations driven by external stimulation, amantadine-induced spontaneous activity was always preceded by the development of subthreshold diastolic depolarizations, which are further characterized in Figure 8. Panel A shows polygraph recordings of transmembrane potentials obtained from a cat papillary muscle stimulated with trains of 21 beats BCL 500 msec ; separated by 20-seconds pauses. Control MDP was --85 mV panel A ; . In panel B, 5 minutes of exposure to amantadine 200 XM ; was sufficient to induce a SDD which reached a peak of 4 mV, 1.0 second after the last stimulus. The amplitude and time to peak of the SDD increased progressively until, at 15 minutes panel C ; , the amplitude was 17 mV. In panel D, after only 15 minutes of washout, there was almost a complete return to control conditions. A common feature of amantadine-induced effects was the appearance of low amplitude oscillations superimposed upon the SDD's. In conjunction, the and parlodel. What is Amantadine
Claims for drugs must be filed no later than December 31, 2005. Physicians, providers, suppliers that enroll in Medicare before May 31, 2005 may also file claims for drugs furnished under this demonstration for dates of service beginning when the provider or supplier completes enrollment. The Medicare co-payment and deductible apply to claims under this demonstration and includes Medicare Advantage MA ; beneficiaries. Beneficiaries participating in the Drug Discount Card program will pay the lesser of 20 percent of the negotiated Drug Discount Sponsor's price for anti-viral medicines, plus $.20. Allowable payment for demonstration drugs will be: Based on 95 percent of the Average Wholesale Price AWP ; for the brand name of Zanamivir and Oseltamivir Phosphate For drugs marketed as bioequivalent or generics Amanhadine and Rimantadine ; , the allowed amount will be based on 90 percent of AWP. Indian Health Service IHS ; hospitals IHS Critical Access Hospitals CAHs ; Rural Health Clinics RHCs ; and Federally Qualified Health Centers FQHCs ; Maryland hospitals under the jurisdiction of Health Services Cost Review Commission HSCRC ; G9017: Amantadlne Hydrocloride, Oral, per 100 mg, for use in a Medicare-approved demonstration project ; , ##TEXT##.76 G9018: Zanamivir, Inhalation Powder Administered Through Inhaler, per 10 mg, for use in a Medicare approved demonstration project ; , .43 G9019: Oseltamivir Phosphate, Oral, per 75 mg, for use in a Medicare-approved demonstration project ; , .99 G9020: Rimantadine Hydrochloride, Oral, per 100 mg, for use in a Medicare-approved demonstration project ; , .65 G9033: Amandatine Hydrocloride, Oral, brand, per 100 mg for use in a Medicare-approved demonstration project ; , .32 G9034: Zanamivir, Inhalation Powder Administered Through Inhaler, brand, per 10 mg, for use in a Medicare-approved demonstration project ; , .43 G9035: Oseltamivir Phosphate, Oral brand, per 75 mg, for use in a Medicare-approved demonstration project ; , .99 G9036: Rimantadine Hydrochloride, Oral brand, per 100 mg, for use in a Medicare-approved demonstration project ; , .17 Page 2 of 4. REFERENCES 1. Piper BF, Rieger PT, Brophy L, et al. Recent advances in the management of biotherapyrelated side effects: fatigue. Oncol Nurs Forum. 1989; 16: 27-34. Dalakas MC, Mock V, Hawkins MJ. Fatigue: definitions, mechanisms, and paradigms for study. Semin Oncol. 1998; 25: 48-53. Aistars J. Fatigue in the cancer patient: a conceptual approach to a clinical problem. Oncol Nurs Forum. 1987; 14: 25-30. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-. Semin Oncol. 1998; 25 suppl 1 ; : 3-8. 5. Sandstrom SK. Nursing management of patients receiving biological therapy. Semin Oncol Nurs. 1996; 12: 152-162. Rieger PT, ed. Biotherapy: A Comprehensive Overview. 2nd ed. Sudbury, Mass: Jones & Barlett; 1995: 129-132. 7. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001; 92: 16641668. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat. 1996; 3: 247-252. Kiley KE, Gale DM. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b. Clin J Oncol Nurs. 1998; 2: 11-16. Teuber G, Bert T, Naumann U, et al. Randomized, placebo-controlled, double-blind trial with interferon- with and without amantadine sulfate in primary interferon- nonresponders with chronic hepatitis C. J Viral Hepat. 2001; 8: 276-283 and lamictal. Others prefer to identify patients with lada who exhibit features of metabolic syndrome as having type 5 diabetes 6. Zulfiqar Ali and Ikhlas A. Khan National Center for Natural Products Research, and Department of Pharmacognosy, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, MS 38677 Abstract Blue cohosh, Caulophyllum thalictroides L. ; Michx. Berberidaceae ; , is recommended to use primarily for women, especially for amenorrhea lack of menstruation ; and dysmenorrhea painful menstruation ; . Native Americans used this plant for rheumatism, dropsy, colic, sore throat, cramp, epilepsy, hysterics, and inflammation of the uterus. A comprehensive phytochemical investigation of blue cohosh resulted in the isolation of 16 compounds belonging to alkaloids and triterpene saponins. Two alkaloids, caulophyllumines A 1 ; and B 2 ; and a saponin, cauloside H 3 ; were found to be new. Their structures were determined by spectroscopic techniques including 1- and 2- Dimensional NMR as well as by chemical analysis. By: dr davis back and wrist pain blog what is carpal tunnel syndrome and can chiropractic help.
Therapeutic or Normal DRUG A Acebutolol Spectral ; Acetaminophen Tylenol ; Acetazolamide Diamox ; Acetohexamide Dymelor ; Acetone Acetonitrile [met: to Cyanide] Acetylsalicylic Acid [as met: Salicylate-for analgesic use] Acetylsalicylic Acid [as met: Salicylate-for rheumatoid arthritis] Actidil Triprolidine ; Actifed Pseudoephedrine ; Triprolidine ; Actron Ketoprofen ; Adalat Nifedipine, Procardia ; Alcaine Proparacaine ; Aldrin Alfenta Alfentanil ; Alfentanil Alfenta ; Allegra Fexofenadine ; Alphaprodine Nisentil ; Alprazolam Xanax ; Aluminum Amanadine Symmetrel ; Ambien Zolpidem ; Aminophylline Theophylline ; Amitriptyline Elavil ; Amitriptyline Elavil ; [ + met: Nortriptyline] Ammonia Amobarbital Amytal ; Amoxapine Asendin ; Amoxapine Asendin ; [ + met: 8-OH-amoxapine] Amphetamine Amytal Amobarbital ; Anafranil Clomipramine ; Anaprox Naproxen ; Analeridine Leritine ; Aniline Ansaid Flubiprofen ; Antabuse Disulfiram ; Antipyrine Aralen Chloroquine ; Arsenic Asendin Amoxapine ; 0.003 - 0.011 0.1 - 0.5 0.01 - 0.045 3.1 - 12 0.05 * 1 - 2.2 0.038 - 0.25 0.5 - 2.5 0.002 - 0.040 0.002 - 0.0062 0.0017 - 0.021 0.03 - 0.11 1-5 0.1 - 0.45 31 - 120 0.5 * 10 - 22 0.38 - 2.5 5-25 0.02 - 0.40 0.02 - 0.062 0.017 - 0.21 0.05 1-3 * 40 * * * * * * 0.1 * 0.05 - 0.17 0.1 - 0.5 0.0017 - 0.021 0.02 - 0.04 0.5 - 1.7 1-5 0.017 - 0.21 0.2 - 0.4 * 1-3 * * 0.0004 - 0.0044 0.050 - 0.077 0.0004 - 0.0044 0.5 - 0.15 - 0.0162 * 0.00015 0.010 - 0.12 0.010 - 0.12 0.018 - 0.021 0.087 - 0.100 0.0025 - 0.0102 0.013 0.006 - 0.031 0.0029 - 0.0272 1-2 0.012 - 0.025 0.012 - 0.025 0.004 - 0.044 0.50 - 0.77 0.004 - 0.044 5 - 1.5 - 0.162 * 0.0015 0.10 - 1.2 0.10 - 1.2 0.18 - 0.210 0.87 - 1.00 0.025 - 0.102 0.13 0.06 - 0.31 0.029 - 0.272 10 - 20 0.12 - 0.25 0.12 - 0.25 * * * * * * 0.00035 * * * * * * 0.1 - 0.05 * 3-4 0.05 - 25 20 - 250 * 0.05 - 0.12 1-2 1.0 - 1.5 2.1 - 5.6 * * 2 - 10 0.5 - 1.2 10 - 20 10 - 100 * 15 * * 20 - 30 * mg% ug ml mg. Amantadine canadaAmatadine, smantadine, amantadne, amantaadine, amantadone, amantadinne, wmantadine, aman6adine, amantadime, amzntadine, amantadin3, amantxdine, amajtadine, amantacine, amatnadine, amantadins, amantaxine, amantafine, amantaine, amantadinee, amwntadine, amamtadine, amsntadine, amanfadine, amantadnie, amantadind, amantarine, amabtadine, amanttadine, amanradine, amaantadine, amantqdine, amantadkne, amangadine, amantadlne, xmantadine, amantdine, ammantadine, amantadin4, amantdaine, amantadibe. | |||
| © 2006-2007 Web-buy.fizwig.com -All Rights Reserved. |
